NCT00973817CompletedPhase 2
Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Subjects With Acute On Chronic Hepatitis (AOCH)
Vital Therapies, Inc.40 sites in 2 countries62 target enrollmentStarted: September 2009Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Vital Therapies, Inc.
- Enrollment
- 62
- Locations
- 40
- Primary Endpoint
- Time to progression at which a 5-point or greater Model for End stage Liver Disease (MELD) score is recorded relative to baseline
Study Overview
Brief Summary
The purpose of this study is to investigate the safety and efficacy of the use of ELAD in patients with diagnosed Acute On Chronic Hepatitis, including Acute Alcoholic Hepatitis.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 67 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age >/= 18</= 67 years; AND
- •Acute decompensation of chronic liver disease over the preceding 30 days; AND
- •MELD score between 18 and 35, inclusive; AND
- •Subject or designated representative must provide Informed Consent
Exclusion Criteria
- •Platelets <50,000mm at baseline; OR
- •Evidence of chronic renal failure as defined by a serum creatinine >/= 2.5mg/dL as measured during the 1-6 month period prior to study entry. (Subject is not excluded with a creatinine >2.5 mg/dL if deemed to be type-1 hepato-renal syndrome); OR
- •Contraindication to renal replacement therapy (hemodialysis or hemofiltration); OR
- •International Normalization Ratio (INR) > 3.5; OR
- •Septic shock as defined by a positive blood culture and two or more of the following:
- •Systolic blood pressure <90mmHg OR mean arterial pressure <60mmHg;
- •Tachypnea > 20 breaths per minute OR a PaCO2<32 mmHg;
- •White blood cell count < 4000 cell/mm3 OR > 12000 cell/mm3 (<4 x 10(9) or >12 x 10(9) cells/L).
- •Evidence of major hemorrhage as indicated by:
- •requiring >/= 4 units packed red blood cells within a 48 hour period prior to Screening, OR
- •hemodynamic instability (sustained pulse > 120 beats/min AND systolic blood pressure < 100 mmHg over one hour)
- •Subjects with a recent history of gastrointestinal hemorrhage who have been successfully treated and remain hemodynamically stable for a period of 48 hours will then be eligible for the study if the investigator determines the subject to be at low risk for rebleeding; OR
- •Evidence (by physical exam, history or lab evaluation) of significant concomitant disease including chronic congestive heart failure, vascular disease, emphysema, AIDS, hepatitis due to herpes virus, Wilson's disease, or Budd-Chiari syndrome; OR
- •Known history of hepatocellular carcinoma beyond the Milan criteria and/or portal vein thrombosis; OR
- •Evidence of spontaneous bacterial peritonitis with uncontrolled infection; OR
- •Evidence of brain death as determined by blood flow studies positive for herniation AND/OR absence of pupillary reflex; OR
- •Systolic blood pressure <85 mmHg OR MAP <50mmHg at baseline; OR
- •Requirement for escalating doses of vasopressor support OR of an alpha-adrenergic agent for one hour or longer AND evidence of hemodynamic instability; OR
- •Subject at maximum vasopressor dose at Screen; OR
- •Clinical or radiographic evidence of a new stroke or intracerebral bleeding; OR
- •Seizures uncontrolled by medication; OR
- •Acute myocardial infarction based on clinical and/or electrocardiographic evidence; OR
- •Lung disease defined by a PaO2<60mmHg on room air, acute respiratory distress syndrome, or a history of severe COPD or interstitial lung disease; OR
- •Pregnancy as determined by beta-HCG results or lactation; OR
- •Participation in another investigational drug, biologic, or device study within 1 month of enrollment. Subjects enrolled in an observational study will be eligible for this trial.
- •Previous liver transplant.
- •Previous participation in a clinical trial involving ELAD.
Outcomes
Primary Outcomes
Time to progression at which a 5-point or greater Model for End stage Liver Disease (MELD) score is recorded relative to baseline
Time Frame: From Baseline up to Study Day 91
This is based on death or the first observed increase of at least 5 points from Baseline MELD score (whichever occurs earlier) at least 24 hours after the ELAD® Treatment Period is ended and up to Study Day 91 (90 days following Baseline).
Secondary Outcomes
- Time to progression at which a 5-point or greater MELD score is recorded relative to baseline(From Baseline up to Study Day 91)
Investigators
Study Sites (40)
Loading locations...
Similar Trials
Completed
Phase 1
Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic InsufficiencyAcute HepatitisChronic HepatitisNCT00771446Vital Therapies, Inc.18
No Longer Available
Not Applicable
Use of the ELAD® in Patients With Liver Failure to Provide Expanded Access With Cost RecoveryLiver FailureNCT00832273Vital Therapies, Inc.
Completed
Phase 2
Phase 2 Evaluation of the ELAD System in the Management of Acute Liver FailureFulminant Hepatic FailureNCT00030225Vital Therapies, Inc.19
Terminated
Phase 3
To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score FailureSevere Acute Alcoholic HepatitisNCT01829347Vital Therapies, Inc.18
Recruiting
Not Applicable
Evaluation of the Effectiveness of Extracorporeal Methods for Removing Mediators of Systemic InflammationRenal Failure AcuteMultiple Organ FailureCardiovascular DiseasesNCT05182723Petrovsky National Research Centre of Surgery20